VenoStent vs Biogen
Side-by-side comparison of AI visibility scores, market position, and capabilities
Houston TX YC W20 clinical-stage AV fistula wrap for dialysis patients with 200-patient RCT underway; $22.8M total ($20M Good Growth/Norwest Series A Jun 2024 + $3.6M NIH grant) targeting vascular access failure competing for dialysis market.
About
VenoStent is a Houston, Texas-based clinical-stage medical device company — backed by Y Combinator (W20) with $22.8 million in total funding including a $20 million Series A in June 2024 led by Good Growth Capital and IAG Capital Partners with $4 million from Norwest Venture Partners, plus a $3.6 million NIH SBIR Phase II Grant — developing SelfWrap, a bioabsorbable perivascular wrap designed to improve arteriovenous (AV) fistula patency rates for chronic kidney disease patients requiring hemodialysis access. Having initiated clinical sites and enrolled first patients in a 200-patient randomized controlled trial (RCT) across multiple US centers in 2024, VenoStent targets the 600,000+ American dialysis patients who depend on reliable vascular access as their lifeline.
Cambridge MA neuroscience biopharma (NASDAQ: BIIB) at $9.7B 2024 revenue; LEQEMBI $87M Q4 (Alzheimer's first-in-class amyloid therapy), SKYCLARYS $102M Q4 (Friedreich's ataxia), MS franchise declining vs. Eli Lilly donanemab.
About
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and commercializing therapies for neurological, neurodegenerative, and neurodevelopmental diseases including Alzheimer's disease, multiple sclerosis, spinal muscular atrophy, and rare neurological conditions through approximately 7,400 employees worldwide. In fiscal year 2024, Biogen reported total revenue of $9.7 billion (-2% year-over-year) and GAAP diluted EPS of $11.18 (+40%), reflecting significant cost-cutting that improved profitability despite modest revenue decline. Revenue decline was driven by continued erosion in the core multiple sclerosis franchise (TECFIDERA, AVONEX, TYSABRI facing generic and biosimilar competition) while new product revenue grew: LEQEMBI (lecanemab, Alzheimer's disease, partnered with Eisai) generated approximately $87 million in Q4 2024 global sales — reflecting the slow but building commercial trajectory of the first drug to slow Alzheimer's cognitive decline — and SKYCLARYS (omaveloxolone, Friedreich's ataxia) generated $102 million in Q4, nearly double the year-earlier period. CEO Christopher Viehbacher, who joined in 2022 from Genentech's parent Roche, has led a strategic restructuring that includes cost reduction, pipeline refocus on high-probability neurology programs, and the LEQEMBI commercial execution through a partnership model with Eisai.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.